Clinical trials: Tumor Immunity
Melanoma, Pancreas Cancer
Integration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in Cancer
The goal of this investigator-initiated tumour profiling study is to analyse the relation between genomic alterations and the tumour immune contexture in patients with advanced melanoma and pancreatic cancer with resistance to…
- Trial name
- SONATA (NCT07796594)
- Testing
- Biopsy
- Where
- Netherlands
- Volunteers
- 180 people
- Sponsor
- Amsterdam UMC, location VUmc
Breast Cancer - Female
Comparison Immune Response in Paravertebral and Erector Spinal Plane Block in Breast Cancer Patients
The goal of this clinical trial is to find the difference in immune response between two types of regional anesthesia in female patients suffering from breast cancer.
- Trial name
- IRPVBESP (NCT07648810)
- Testing
- Regional Anesthetic Injection, Blood draw for the laboratory assessment
- Volunteers
- 56 people
- Sponsor
- Clinical Hospital Center Rijeka
Hematological Malignancies B
Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B
Cancer-specific splice variants gain significant interest as they generate neo-antigens, that could be targeted by immune cells.
- Trial name
- Epitopes-LNH01 (NCT02844491)
- Testing
- additional biological samples
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Breast Cancer, HER2-positive Breast Cancer
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
The purpose of this study is to learn more about how to treat patients with a diagnosis of diagnosis of Human Epidermal Growth Factor Receptor 2/neu (HER-2/neu) positive breast cancer in the past, who were previously treated with…
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, HER-2 Gene Amplification, HER2 Positive Breast Carcinoma
- Trial name
- NCT03630809
- Testing
- HER2 DC1 Vaccine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
BRAF V600E Mutation Present, BRAF V600K Mutation Present
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
This randomized phase I trial studies the side effects and best way to give ipilimumab with or without dabrafenib, trametinib and/or nivolumab in treating patients with melanoma that has spread to other parts of the body…
- Conditions
- BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01940809
- Testing
- Dabrafenib, Ipilimumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Anesthesia, Cervical Cancer
Effects of Anesthesia on Tumor Immunity and Insulin Resistance During Perioperative Period
To evaluate the effects of preoperative oral carbohydrate on postoperative insulin resistance and tumor immunity in cervical cancer patients with neoadjuvant chemotherapy.
- Conditions
- Anesthesia, Cervical Cancer, Carbohydrate, Tumor Immunity
- Trial name
- NCT03872635
- Testing
- oral carbohydrate liquid
- Where
- 2 sites in China
- Volunteers
- 80 people
- Sponsor
- Fujian Cancer Hospital
Breast Cancer
Exercise Study for Breast Cancer Survivors
This study evaluates the link between muscle health and immune health in breast cancer survivors. Regular exercise is known to improve overall survival in cancer patients but the mechanism is not known.
- Trial name
- NCT04208074
- Testing
- Exercise Intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- San Diego Biomedical Research Institute
Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell)
Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples
Lung cancer is the leading cause of cancer-related death worldwide, with nearly 2.48 million cases and 1.8 million deaths in 2022.
- Trial name
- RICEPS-2 (NCT07163507)
- Testing
- Blood sample, sputum sample
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing…
- Conditions
- Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT07020533
- Testing
- Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation
- Where
- 3 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Breast Cancer Female, Chemotherapy Effect
Quality of Life Improvement During Chemotherapy
This study is a randomized controlled trial, taking place at the University Hospital Basel (CH). It aims at the alleviation of breast cancer patients' life quality during chemotherapy.
- Trial name
- QoLMa (NCT04694885)
- Testing
- Structured Hypnotherapy
- Where
- Switzerland
- Volunteers
- 62 people
- Sponsor
- University Hospital, Basel, Switzerland
Soft-tissue Sarcomas
Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
Assessment of the efficacy and safety of trabectedin and metronomic cyclophosphamide (CP) in patients with advanced pretreated soft-tissue sarcomas, once the Maximum Tolerated Dose (MTD) have been determined (phase I trial).
- Trial name
- TARMIC (NCT02805725)
- Testing
- Phase 1: Trabectedin, Phase 2: Trabectedin, Phase 1: Cyclophosphamide
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Institut Bergonié
HPV Infection
HPV Vaccine Immunity in High-risk Women
This is a single arm immunological study based in Vietnam. The study will examine human papillomavirus (HPV) vaccine responses in high-risk women (female-sex-worker; FSW).
- Trial name
- NCT04590521
- Testing
- Gardasil®, Merck
- Where
- Vietnam
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Non-Hodgkin's Lymphoma
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkin's lymphoma (NHL) or refractory NHL, and to test the immunity of study subjects after receiving four treatments with rituximab.
- Trial name
- NCT00090038
- Testing
- rituximab
- Where
- 45 sites in United States, Austria and 9 more
- Volunteers
- 168 people
- Sponsor
- Biogen
Breast Cancer
STRIDE - STimulating Immune Response In aDvanced brEast Cancer
EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).
- Trial name
- STRIDE (NCT00925548)
- Testing
- Tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
- Where
- 29 sites in United States, Australia and 10 more
- Volunteers
- 16 people
- Sponsor
- EMD Serono
Cell Function
In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and Patients
Peripheral blood mononuclear cells (PBMC) will be collected from healthy volunteers and patients who present with different diseases that involve or implicate the immune system dysregulation (HIV infection, autoimmune diseases…
- Trial name
- NCT00342485
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Cancer
Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1
Recent scientific advances have shown the important role of immune system against cancer. Today, many immunological biotherapy like anti-PD1/PDL-1 are available in cancer treatment and generate durable clinical responses in some…
- Trial name
- ITHER (NCT02840058)
- Testing
- Biological samples, Anti PD1/PDL1 treatment
- Where
- 4 sites in France
- Volunteers
- 295 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Advanced Cancer, ADCC
Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells
NK cells can persist and expand in vivo following adoptive transfer and may have a role in the treatment of late stage malignancies.
- Conditions
- Advanced Cancer, ADCC, NK Cell Mediated Immunity, Nimotuzumab
- Trial name
- NCT03554889
- Testing
- NK Cell adaptive transfer, Nimotuzumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Hangzhou Cancer Hospital
Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming
Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study
The goal of this clinical trial is to learn whether a high- and low-dose radiotherapy regimen followed by anti-angiogenic TKI and anti-PD-1 antibody therapy works to treat advanced metastatic colorectal cancer.
- Conditions
- Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response
- Trial name
- TRIUNITE-07 (NCT07467590)
- Testing
- High- and Low-Dose Radiotherapy, Anti-Angiogenic TKI and Anti-PD-1 Therapy
- Volunteers
- 33 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Advanced Melanoma, Stage III and IV Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.
A dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanomas.
- Trial name
- NCT00688090
- Testing
- Biological: MKC1106-MT, Biological: MKCC1106-MT
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Mannkind Corporation
Solid Cancers
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy
This is a translational, open-label, multi-site, prospective cohort study aiming to identify and to monitor immunological biomarkers associated with therapeutic response to immune checkpoints blockade (ICB), in patients with…
- Trial name
- MINER (NCT03514368)
- Testing
- Patients treated with immune checkpoint blockade
- Where
- 3 sites in France
- Volunteers
- 770 people
- Sponsor
- Institut Claudius Regaud